Benjamin N Cheyette, MD
Psychiatry · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 15
- 2 carriers
- Office
- 1
- Since medical school
- 31 years
- University of California, Geffen School of Medicine, 1995
Offices
1 location · Mindful Health Solutions A Professional Medical Corporation · 55 clinicians in this group
Looking this up.
Plans that list them
15 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cheyette’s office at (844) 867-8444 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
15 of 15 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G86539 · Current
Licensed to practise in California · since 2002 · expires 2028-06-30 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Psychiatry
Original Medicare doctor bills
$67,537
Medicare paid this office $67,537 for 35 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | 11 | $42,391 | $118 |
| Return visit (30+ min) | 34 | $15,140 | $116 |
| Psychotherapy with evaluation and management visit, 30 minutes | 22 | $3,479 | $61 |
| Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | 11 | $2,279 | $207 |
Who their Medicare patients are
35 Original Medicare patients in 2024. Average age 71 · Health risk score 0.95. At or below the middle of the specialty; the typical psychiatry clinician is at 1.35.
Conditions among them: Depression 75% · High blood pressure 46%.
The office billed $342,520, Medicare allowed $86,589 and paid $67,537; for 581 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 35 | 581 | 71 | 0.95 | $342,520 | $67,537 |
| 2023 | 24 | 429 | 72 | 1.29 | $256,165 | $52,969 |
| 2022 | 26 | 325 | 72 | 1.06 | $126,901 | $28,463 |
| 2021 | 22 | 411 | 72 | 1.12 | $165,664 | $42,024 |
| 2020 | 68 | 635 | 72 | 1.03 | $109,547 | $38,688 |
| 2019 | 54 | 422 | 71 | 1.03 | $95,308 | $33,141 |
| 2018 | 65 | 122 | 66 | 2.35 | $48,025 | $11,154 |
| 2017 | 45 | 56 | 57 | 1.69 | $33,094 | $5,869 |
| 2016 | 19 | 20 | 60 | 1.90 | $11,133 | $1,971 |
| 2015 | 17 | 21 | 50 | 1.58 | $5,967 | $1,383 |
| 2014 | 13 | 15 | 62 | 2.34 | $6,357 | $1,610 |
| 2013 | 26 | 37 | 61 | 1.76 | $17,136 | $4,132 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 15 | $5,004 | $114 |
| Psychotherapy with evaluation and management visit, 30 minutes | 22 | $4,784 | $58 |
| Short return visit (20+ min) | 20 | $3,680 | $80 |
2022: 3 services
| Psychotherapy with evaluation and management visit, 30 minutes | 24 | $5,879 | $54 |
| Return visit (30+ min) | 17 | $5,670 | $89 |
| Short return visit (20+ min) | 19 | $2,944 | $58 |
2021: 4 services
| Psychotherapy with evaluation and management visit, 30 minutes | 20 | $6,565 | $57 |
| Return visit (30+ min) | 18 | $5,871 | $92 |
| Short return visit (20+ min) | 16 | $3,550 | $65 |
| Assessment of emotional or behavioral problems | 13 | $248 | $5 |
2020: 5 services
| Return visit (30+ min) | 62 | $18,153 | $92 |
| Psychotherapy with evaluation and management visit, 30 minutes | 62 | $12,673 | $60 |
| Short return visit (20+ min) | 18 | $2,056 | $71 |
| Psychiatric diagnostic evaluation with medical services | 14 | $1,545 | $110 |
| Psychiatric services complicated by communication factor | 54 | $1,457 | $9 |
2019: 4 services
| Return visit (30+ min) | 50 | $17,996 | $98 |
| Psychotherapy with evaluation and management visit, 30 minutes | 45 | $9,143 | $61 |
| Psychiatric diagnostic evaluation with medical services | 27 | $3,051 | $113 |
| Psychiatric services complicated by communication factor | 15 | $267 | $10 |
2018: 3 services
| Psychiatric diagnostic evaluation with medical services | 29 | $3,690 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,559 | $62 |
| Psychiatric diagnostic evaluation with medical services | 14 | $1,848 | $123 |
2017: 1 service
| Psychiatric diagnostic evaluation with medical services | 30 | $3,709 | $124 |
Drugs they prescribed that Part D paid
$48,922
Pharmacies billed $48,922 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 437) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
397 generic and 40 brand-name prescriptions · $48,922 in drug cost · 18 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Spravato | 13 | $16,417 | $1,263 |
| Atomoxetine | 12 | $1,240 | $103 |
| Aripiprazole | 19 | $558 | $29 |
| Escitalopram | 31 | $519 | $17 |
| Fluoxetine | 43 | $457 | $11 |
See all 14 drugs
| Spravato | 13 | $16,417 | $1,263 |
| Atomoxetine | 12 | $1,240 | $103 |
| Aripiprazole | 19 | $558 | $29 |
| Escitalopram | 31 | $519 | $17 |
| Fluoxetine | 43 | $457 | $11 |
| Lithium Carbonate | 13 | $418 | $32 |
| Gabapentin | 23 | $393 | $17 |
| Clonazepam | 38 | $369 | $10 |
| Methylphenidate | 13 | $283 | $22 |
| Lamotrigine | 15 | $203 | $14 |
| Alprazolam | 30 | $198 | $7 |
| Lorazepam | 40 | $195 | $5 |
| Duloxetine | 12 | $151 | $13 |
| Nortriptyline | 16 | $41 | $3 |
Year by year
| 2024 | 437 | 46 | 0% (0) | 9% | $48,922 |
| 2023 | 318 | 36 | 0% (0) | 13% | $62,160 |
| 2022 | 335 | 32 | 0% (0) | 13% | $55,909 |
| 2021 | 359 | 68 | 0% (0) | 7% | $34,794 |
| 2020 | 921 | 89 | 0% (0) | 6% | $50,561 |
| 2019 | 690 | 60 | 0% (0) | 7% | $45,753 |
| 2018 | 74 | 25 | 0% (0) | None | $2,848 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Spravato | 20 | $23,225 | $1,161 |
| Trintellix | 12 | $16,725 | $1,394 |
| Atomoxetine | 13 | $1,125 | $87 |
| Escitalopram | 25 | $1,034 | $41 |
| Aripiprazole | 18 | $791 | $44 |
| Fluoxetine | 28 | $445 | $16 |
| Clonazepam | 33 | $410 | $12 |
| Gabapentin | 11 | $282 | $26 |
| Methylphenidate | 11 | $231 | $21 |
| Lorazepam | 18 | $178 | $10 |
| Venlafaxine Hcl Er | 15 | $127 | $8 |
| Zolpidem | 16 | $123 | $8 |
2022: 12 drugs
| Spravato | 20 | $21,383 | $1,069 |
| Trintellix | 13 | $17,227 | $1,325 |
| Aripiprazole | 15 | $2,660 | $177 |
| Escitalopram | 27 | $512 | $19 |
| Buspirone | 13 | $352 | $27 |
| Clonazepam | 27 | $296 | $11 |
| Lithium Carbonate | 12 | $283 | $24 |
| Paroxetine | 15 | $234 | $16 |
| Zolpidem | 16 | $199 | $12 |
| Lorazepam | 19 | $140 | $7 |
| Fluoxetine | 21 | $116 | $6 |
| Alprazolam | 16 | $79 | $5 |
2021: 12 drugs
| Mirtazapine | 18 | $989 | $55 |
| Aripiprazole | 18 | $951 | $53 |
| Duloxetine | 15 | $567 | $38 |
| Escitalopram | 20 | $462 | $23 |
| Bupropion Hcl Sr | 22 | $462 | $21 |
| Fluoxetine | 27 | $440 | $16 |
| Paroxetine | 11 | $381 | $35 |
| Buspirone | 17 | $338 | $20 |
| Lorazepam | 32 | $278 | $9 |
| Gabapentin | 15 | $268 | $18 |
| Clonazepam | 18 | $154 | $9 |
| Trazodone | 15 | $122 | $8 |
2020: 26 drugs
| Prozac | 11 | $10,263 | $933 |
| Fetzima | 11 | $5,226 | $475 |
| Mirtazapine | 71 | $2,814 | $40 |
| Duloxetine | 41 | $1,877 | $46 |
| Aripiprazole | 22 | $1,744 | $79 |
| Bupropion Xl | 30 | $1,334 | $44 |
| Clonazepam | 58 | $1,152 | $20 |
| Bupropion Hcl Sr | 29 | $710 | $24 |
| Olanzapine | 17 | $691 | $41 |
| Buspirone | 43 | $680 | $16 |
| Fluoxetine | 67 | $592 | $9 |
| Amitriptyline | 19 | $571 | $30 |
| Sertraline | 25 | $453 | $18 |
| Venlafaxine Hcl Er | 24 | $434 | $18 |
| Dextroamphetamine-Amphetamine | 14 | $416 | $30 |
| Quetiapine | 27 | $394 | $15 |
| Gabapentin | 15 | $390 | $26 |
| Lorazepam | 83 | $373 | $4 |
| Trazodone | 33 | $372 | $11 |
| Escitalopram | 27 | $365 | $14 |
| Paroxetine | 24 | $221 | $9 |
| Lamotrigine | 12 | $208 | $17 |
| Diazepam | 19 | $171 | $9 |
| Bupropion | 12 | $156 | $13 |
| Alprazolam | 21 | $102 | $5 |
| Zolpidem | 13 | $42 | $3 |
2019: 22 drugs
| Viibryd | 11 | $5,688 | $517 |
| Bupropion Xl | 44 | $2,635 | $60 |
| Clonazepam | 51 | $1,551 | $30 |
| Duloxetine | 41 | $1,500 | $37 |
| Ziprasidone | 17 | $954 | $56 |
| Trazodone | 27 | $713 | $26 |
| Venlafaxine Hcl Er | 27 | $647 | $24 |
| Risperidone | 14 | $584 | $42 |
| Buspirone | 20 | $520 | $26 |
| Gabapentin | 18 | $481 | $27 |
| Amitriptyline | 16 | $436 | $27 |
| Bupropion Hcl Sr | 17 | $393 | $23 |
| Fluoxetine | 24 | $387 | $16 |
| Methylphenidate | 11 | $342 | $31 |
| Dextroamphetamine-Amphetamine | 12 | $333 | $28 |
| Lorazepam | 68 | $312 | $5 |
| Alprazolam | 21 | $234 | $11 |
| Olanzapine | 12 | $230 | $19 |
| Zolpidem | 15 | $179 | $12 |
| Escitalopram | 13 | $153 | $12 |
| Diazepam | 15 | $138 | $9 |
| Lithium Carbonate | 16 | $123 | $8 |
Money from drug and device companies
$674 in 2025
| 2025 | 8 | 29 | None | $674 |
| 2024 | 11 | 26 | None | $669 |
| 2023 | 13 | 31 | None | $673 |
| 2022 | 7 | 10 | None | $229 |
| 2021 | 9 | 32 | None | $701 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Vraylar | $164 | 12 payments
|
| Tris Pharma | Dyanavel Xr | $142 | 2 payments
|
| Vanda Pharmaceuticals | Fanapt | $107 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $91 | 5 payments
|
| Janssen Pharmaceuticals | Spravato | $61 | 2 payments
|
| Axsome Therapeutics | Auvelity | $53 | 2 payments
|
See all 29 published payments
| Abbvie | Meals · 2025-12-10 | Vraylar | $23 |
| Abbvie | Meals · 2025-11-13 | Vraylar | $10 |
| Abbvie | Meals · 2025-11-13 | Vraylar | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-05 | Cobenfy | $16 |
| Axsome Therapeutics | Meals · 2025-11-04 | Auvelity | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-03 | Cobenfy | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-28 | Cobenfy | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-20 | Cobenfy | $21 |
| Abbvie | Meals · 2025-10-07 | Vraylar | $24 |
| Vanda Pharmaceuticals | Meals · 2025-08-12 | Fanapt | $17 |
| Axsome Therapeutics | Meals · 2025-08-12 | Auvelity | $26 |
| Tris Pharma | Meals · 2025-07-17 | Dyanavel Xr | $119 |
| Tris Pharma | Meals · 2025-07-11 | Dyanavel Xr | $23 |
| Abbvie | Meals · 2025-07-09 | Vraylar | $10 |
| Vanda Pharmaceuticals | Meals · 2025-07-02 | Fanapt | $30 |
| Abbvie | Meals · 2025-06-11 | Vraylar | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-02 | Cobenfy | $26 |
| Janssen Pharmaceuticals | Meals · 2025-05-29 | Spravato | $29 |
| Abbvie | Meals · 2025-05-22 | Vraylar | $9 |
| Vanda Pharmaceuticals | Meals · 2025-05-15 | Fanapt | $32 |
| Lundbeck | Meals · 2025-05-08 | Rexulti | $26 |
| Abbvie | Meals · 2025-04-22 | Vraylar | $26 |
| Abbvie | Meals · 2025-04-09 | Vraylar | $10 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-04-02 | Caplyta | $30 |
| Abbvie | Meals · 2025-03-24 | Vraylar | $8 |
| Vanda Pharmaceuticals | Meals · 2025-03-13 | Fanapt | $27 |
| Abbvie | Meals · 2025-01-29 | Vraylar | $10 |
| Abbvie | Meals · 2025-01-14 | Vraylar | $11 |
| Janssen Pharmaceuticals | Meals · 2025-01-08 | Spravato | $32 |
See earlier years (2024, 2023, 2022, 2021)
2024: $669
| Lundbeck | Rexulti | $241 | 8 payments
|
| Janssen Pharmaceuticals | Spravato | $105 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $72 | 3 payments
|
| Abbvie | Vraylar | $61 | 3 payments
|
| Noven Therapeutics | Secuado | $42 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $32 | 1 payment
|
| Tris Pharma | Dyanavel Xr | $30 | 1 payment
|
| Axsome Therapeutics | Auvelity | $28 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $21 | 1 payment
|
| Ironshore Pharmaceuticals | Jornay Pm | $21 | 1 payment
|
| Supernus Pharmaceuticals | Qelbree | $17 | 1 payment
|
2023: $673
| AbbVie | Vraylar | $152 | 9 payments
|
| Vanda Pharmaceuticals | Hetlioz | $142 | 6 payments
|
| Lundbeck | Rexulti | $85 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $59 | 2 payments
|
| Janssen Pharmaceuticals | Spravato | $52 | 2 payments
|
| Tris Pharma | Dyanavel Xr | $42 | 2 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $26 | 1 payment
|
| Alkermes | Aristada | $24 | 1 payment
|
| Bausch Health US | Aplenzin | $20 | 1 payment
|
| Otsuka America Pharmaceutical | Abilify Maintena | $20 | 1 payment
|
| Axsome Therapeutics | Auvelity | $19 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $18 | 1 payment
|
| Supernus Pharmaceuticals | Qelbree | $13 | 1 payment
|
2022: $229
| Iti | Caplyta | $62 | 3 payments
|
| Corium | Azstarys | $47 | 2 payments
|
| Abbvie | Vraylar | $29 | 1 payment
|
| Neurocrine Biosciences | Ingrezza | $24 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $23 | 1 payment
|
| Alfasigma USA | None | $22 | 1 payment
|
| Supernus Pharmaceuticals | Qelbree | $22 | 1 payment
|
2021: $701
| AbbVie | Vraylar | $185 | 12 payments
|
| Tris Pharma | Quillivant | $181 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $62 | 3 payments
|
| Lundbeck | Brintellix | $56 | 3 payments
|
| Bausch Health US | Aplenzin | $53 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $52 | 2 payments
|
| Iti | Caplyta | $47 | 2 payments
|
| Otsuka America Pharmaceutical | Rexulti | $35 | 2 payments
|
| Sunovion Pharmaceuticals | Latuda | $31 | 2 payments
|
Professional record
- NPI
- 1093733198
- Licence
- CA G86539California G86539: Current · expires 2028-06-30
- Trained
- University of California, Geffen School of Medicine, 1995 · 31 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G865390
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 1860 El Camino Real Ste 250, Burlingame, CA, 94010
- NPI first listed
- 2006-07-17
- NPI last updated
- 2021-01-21
- NPI record certified
- 2021-01-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 301 Industrial Rd, San Carlos, CA, 94070 · 401 Parnassus Ave, San Francisco, CA, 94143